Irene Kida Minja
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Irene Kida Minja has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuel Balandya
Muhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania
5 shared publications - Julie Makani
Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
5 shared publications - Agnes Jonathan
Department of Development Studies, School of Public Health and Social Sciences, Muhimbili University of Health and Allied Sciences, Dar es Salaam P.O. Box 65001, Tanzania
4 shared publications - Ritah Francis Mutagonda
Department of Clinical Pharmacy and Pharmacology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
4 shared publications Agnes Jonathan
Sickle Pan-African Research Consortium (SPARCO) – Tanzania, Dar es Salaam, Tanzania
3 shared publications- David Thomas Myemba
School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 17, 1-11
Prevalence, Predictors, and Management of Acute Chest Syndrome in Patients with Sickle Cell Disease at Muhimbili National Hospital, Tanzania: A Retrospective Study
Background: Acute Chest Syndrome (ACS) is a potentially life-threatening complication of Sickle Cell Disease (SCD), contributing significantly to hospitalizations and mortality. While extensively studied in high-income settings, there is limited data on its prevalence, associated factors, and treatment patterns in Tanzania. Objective: To determine the prevalence, predictors, and management of ACS among SCD patients admitted at Muhimbili National Hospital (MNH), Dar es Salaam, between January 2019 and December 2024. Methods: A retrospective study was conducted using medical records of 1,257 SCD patients admitted to MNH. Data on demographics, clinical and laboratory characteristics, and treatment interventions were extracted and analyzed. Modified Poisson regression was used to identify factors associated with ACS. Results: The prevalence of ACS was 24.3%. ACS was more likely among children under the age of five years compared to adults above 17 years (adjusted prevalence ratio [aPR] = 2.04, 95% CI: 1.76– 2.38), in patients with upper respiratory tract infections (aPR = 1.62, 95% CI: 1.47– 1.79) and in those with vaso-occlusive crises (aPR = 2.24, 95% CI: 2.12– 2.38), while the use of hydroxyurea (aPR = 0.78, 95% CI: 0.78– 0.79) and a history of asthma (aPR = 0.37, 95% CI: 0.27– 0.47) were associated with a lower prevalence of ACS. Treatment offered included antibiotics (94.4%), pain management (87.2%), intravenous hydration (76.7%), oxygen therapy (43.9%), simple top-up blood transfusion (42.0%) and mechanical ventilation (9.8%). Exchange transfusion was underutilized (0.7%). Conclusion: ACS remains a common complication among patients with SCD admitted to MNH, particularly among younger patients and those presenting with upper respiratory tract infections or vaso-occlusive crises. Hydroxyurea use and a history of asthma were associated with a lower prevalence of ACS in this cohort. Exchange transfusion was the least utilized treatment modality despite current recommendations. These findings highlight the need to strengthen preventive strategies, improve access to hydroxyurea, and address barriers to advanced ACS management, including exchange transfusion.
- 1 October 2026
- Published by Taylor & Francis in Journal of Blood Medicine
- Vol. ume 17, 1-11
Open AccessPrevalence, Predictors, and Management of Acute Chest Syndrome in Patients with Sickle Cell Disease at Muhimbili National Hospital, Tanzania: A Retrospective Study
Background: Acute Chest Syndrome (ACS) is a potentially life-threatening complication of Sickle Cell Disease (SCD), contributing significantly to hospitalizations and mortality. While extensively studied in high-income settings, there is limited data on its prevalence, associated factors, and treatment patterns in Tanzania. Objective: To determine the prevalence, predictors, and management of ACS among SCD patients admitted at Muhimbili National Hospital (MNH), Dar es Salaam, between January 2019 and December 2024. Methods: A retrospective study was conducted using medical records of 1,257 SCD patients admitted to MNH. Data on demographics, clinical and laboratory characteristics, and treatment interventions were extracted and analyzed. Modified Poisson regression was used to identify factors associated with ACS. Results: The prevalence of ACS was 24.3%. ACS was more likely among children under the age of five years compared to adults above 17 years (adjusted prevalence ratio [aPR] = 2.04, 95% CI: 1.76– 2.38), in patients with upper respiratory tract infections (aPR = 1.62, 95% CI: 1.47– 1.79) and in those with vaso-occlusive crises (aPR = 2.24, 95% CI: 2.12– 2.38), while the use of hydroxyurea (aPR = 0.78, 95% CI: 0.78– 0.79) and a history of asthma (aPR = 0.37, 95% CI: 0.27– 0.47) were associated with a lower prevalence of ACS. Treatment offered included antibiotics (94.4%), pain management (87.2%), intravenous hydration (76.7%), oxygen therapy (43.9%), simple top-up blood transfusion (42.0%) and mechanical ventilation (9.8%). Exchange transfusion was underutilized (0.7%). Conclusion: ACS remains a common complication among patients with SCD admitted to MNH, particularly among younger patients and those presenting with upper respiratory tract infections or vaso-occlusive crises. Hydroxyurea use and a history of asthma were associated with a lower prevalence of ACS in this cohort. Exchange transfusion was the least utilized treatment modality despite current recommendations. These findings highlight the need to strengthen preventive strategies, improve access to hydroxyurea, and address barriers to advanced ACS management, including exchange transfusion.
- Open Access
- 4 March 2026
- Published by Taylor & Francis in Hemoglobin
- Vol. 50 (2) , 111-120
SickleInAfrica Consortium: A Seven-Country Study Evaluating the Performance of Dried Blood Spot Point-of-Care Testing in Newborn Screening for Sickle Cell Disease
Sickle cell disease (SCD) is caused by an inherited single-nucleotide substitution in both copies of the β-globin gene [HBB(Glu7Val)]. The sickle-cell mutation results in the production of an abnor...
- 4 March 2026
- Published by Taylor & Francis in Hemoglobin
- Vol. 50 (2) , 111-120
Open AccessSickleInAfrica Consortium: A Seven-Country Study Evaluating the Performance of Dried Blood Spot Point-of-Care Testing in Newborn Screening for Sickle Cell Disease
Sickle cell disease (SCD) is caused by an inherited single-nucleotide substitution in both copies of the β-globin gene [HBB(Glu7Val)]. The sickle-cell mutation results in the production of an abnor...
- Open Access
- 1 December 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (12) , e0005435
Oral health knowledge among primary school adolescents: A cross-sectional study from Maasai populated areas in Tanzania
Oral health knowledge (OHK) is vital for maintenance of good oral health. However, poor oral health remains a significant burden for individuals globally. This study aimed to assess OHK by ethnicity and its covariates in terms of sociodemographic, clinical oral health status and dental health care utilization among primary school adolescents in rural Maasai populated areas in Tanzania. Using a two-stage cluster sample design, we randomly selected 23 out of 66 eligible rural schools in Arusha region, where a total of 906 (91.6%) adolescents aged 12–14 years accepted to participate an interview and an oral clinical examination. The interview included questions on socio-demographic factors and oral health related behavior, while clinical examination included oral hygiene status, gingival bleeding, DMFT, dental fluorosis and dental erosion. OHK was assessed by asking six questions whereby the higher the sum-score in the index, the higher the knowledge for the adolescent towards oral health. Good OHK was observed on 65.1% (590/906) of the adolescents, whereby good OHK in non-Maasai and Maasai were 79.5% and 61.4%, respectively. For the whole group of Maasais and non-Maasais, clinical variables (oral hygiene status, gingival bleeding, DMFT, dental fluorosis and dental erosion) were not associated with good OHK. However, for the non-Maasai group, having less dental fluorosis was associated with good OHK. Modified Poisson regression analysis revealed that being a non-Maasai (APR = 1.2, 95% CI: 1.1-1.4), having a mother with higher education level (APR = 1.2, 95% CI: 1.1-1.4) and ever visited a dentist for dental check-up (APR = 1.3, 95% CI: 1.1-1.4) were significant predictors for having good OHK. A slight majority of the adolescents investigated had good OHK which was significantly associated with ethnicity, maternal education level and ever visited for dental check-up. There is a need to improve OHK, and emphasize adoption of oral disease prevention efforts.
- 1 December 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (12) , e0005435
Open AccessOral health knowledge among primary school adolescents: A cross-sectional study from Maasai populated areas in Tanzania
Oral health knowledge (OHK) is vital for maintenance of good oral health. However, poor oral health remains a significant burden for individuals globally. This study aimed to assess OHK by ethnicity and its covariates in terms of sociodemographic, clinical oral health status and dental health care utilization among primary school adolescents in rural Maasai populated areas in Tanzania. Using a two-stage cluster sample design, we randomly selected 23 out of 66 eligible rural schools in Arusha region, where a total of 906 (91.6%) adolescents aged 12–14 years accepted to participate an interview and an oral clinical examination. The interview included questions on socio-demographic factors and oral health related behavior, while clinical examination included oral hygiene status, gingival bleeding, DMFT, dental fluorosis and dental erosion. OHK was assessed by asking six questions whereby the higher the sum-score in the index, the higher the knowledge for the adolescent towards oral health. Good OHK was observed on 65.1% (590/906) of the adolescents, whereby good OHK in non-Maasai and Maasai were 79.5% and 61.4%, respectively. For the whole group of Maasais and non-Maasais, clinical variables (oral hygiene status, gingival bleeding, DMFT, dental fluorosis and dental erosion) were not associated with good OHK. However, for the non-Maasai group, having less dental fluorosis was associated with good OHK. Modified Poisson regression analysis revealed that being a non-Maasai (APR = 1.2, 95% CI: 1.1-1.4), having a mother with higher education level (APR = 1.2, 95% CI: 1.1-1.4) and ever visited a dentist for dental check-up (APR = 1.3, 95% CI: 1.1-1.4) were significant predictors for having good OHK. A slight majority of the adolescents investigated had good OHK which was significantly associated with ethnicity, maternal education level and ever visited for dental check-up. There is a need to improve OHK, and emphasize adoption of oral disease prevention efforts.
- Open Access
- 13 March 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (3) , e017154
Strengthening global partnerships for sustainable sickle cell disease care: insights from SickleInAfrica at the 77th United Nations General Assembly and the US-Africa Leaders’ Summit
Background: Addressing sickle cell disease (SCD) is crucial for achieving health-related Sustainable Development Goals, particularly in Africa. The region is significantly affected, with 78.7% of patients with SCD residing in sub-Saharan Africa and over 515 000 newborns diagnosed annually. Historically, African health systems have struggled to provide optimal care for patients with SCD, resulting in high under-5 mortality and severe childhood morbidity. Scientific innovations and stakeholder engagement offer hope for improving SCD outcomes. Objective: To explore the role of high-level partnerships and scientific innovation in advancing SCD care and research in Africa, focusing on the contributions and strategic engagements of the SickleInAfrica, as highlighted at the 77th United Nations General Assembly (UNGA) and the US-Africa Leaders’ Summit. Approach: SickleInAfrica, comprising eight countries, leverages a robust infrastructure for SCD research and care. The consortium has established a comprehensive SCD database and a patient registry in each of the consortium sites that includes demographic details, clinical diagnosis, management details and follow-ups/visits. Currently, over 34 000 patients with SCD are enrolled, making it the largest globally. It has also contextually adapted clinical guidelines for managing SCD for all levels of care. The high-level engagements at the 77th UNGA held in September 2022 in New York and the US-Africa Leaders’ Summit held in December 2022 in Washington DC promoted SCD awareness and partnerships. The UNGA session emphasised biomedical science, implementation research and partnerships in therapeutic development, while the US-Africa Leaders’ Summit session focused on Global Partnerships for SCD: Advancing Science and Technology for Health in Africa. Conclusions: High-level engagements facilitate cross-border dialogues, underscoring the importance of partnerships from grassroots to global alliances. Key outcomes include increased awareness, policy advocacy and the establishment of SCD Centres of Excellence and genomics capacity-building initiatives. Sustainable efforts require robust partnerships, government involvement, community awareness and equitable access to advanced therapies.
- 13 March 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (3) , e017154
Open AccessStrengthening global partnerships for sustainable sickle cell disease care: insights from SickleInAfrica at the 77th United Nations General Assembly and the US-Africa Leaders’ Summit
Background: Addressing sickle cell disease (SCD) is crucial for achieving health-related Sustainable Development Goals, particularly in Africa. The region is significantly affected, with 78.7% of patients with SCD residing in sub-Saharan Africa and over 515 000 newborns diagnosed annually. Historically, African health systems have struggled to provide optimal care for patients with SCD, resulting in high under-5 mortality and severe childhood morbidity. Scientific innovations and stakeholder engagement offer hope for improving SCD outcomes. Objective: To explore the role of high-level partnerships and scientific innovation in advancing SCD care and research in Africa, focusing on the contributions and strategic engagements of the SickleInAfrica, as highlighted at the 77th United Nations General Assembly (UNGA) and the US-Africa Leaders’ Summit. Approach: SickleInAfrica, comprising eight countries, leverages a robust infrastructure for SCD research and care. The consortium has established a comprehensive SCD database and a patient registry in each of the consortium sites that includes demographic details, clinical diagnosis, management details and follow-ups/visits. Currently, over 34 000 patients with SCD are enrolled, making it the largest globally. It has also contextually adapted clinical guidelines for managing SCD for all levels of care. The high-level engagements at the 77th UNGA held in September 2022 in New York and the US-Africa Leaders’ Summit held in December 2022 in Washington DC promoted SCD awareness and partnerships. The UNGA session emphasised biomedical science, implementation research and partnerships in therapeutic development, while the US-Africa Leaders’ Summit session focused on Global Partnerships for SCD: Advancing Science and Technology for Health in Africa. Conclusions: High-level engagements facilitate cross-border dialogues, underscoring the importance of partnerships from grassroots to global alliances. Key outcomes include increased awareness, policy advocacy and the establishment of SCD Centres of Excellence and genomics capacity-building initiatives. Sustainable efforts require robust partnerships, government involvement, community awareness and equitable access to advanced therapies.
- Open Access
- 27 January 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (1) , e017878
Strengthening advanced therapy for sickle cell disease in Africa: experience from sickle cell disease centre in Dar es Salaam, Tanzania
Despite progress in healthcare services for individuals living with sickle cell disease (SCD) in Africa, substantial gaps remain in advanced treatments for SCD. To help address this burden, Tanzania has established one of the largest single-centre SCD programmes in the world and developed an advanced therapy programme for SCD focused on patient engagement and advocacy, clinical activities involving exchange blood transfusion (ExBT) and haematopoietic stem cell transplant (HSCT), gene therapy (GT) preparedness, and enabling partnerships. This report describes the programme’s genesis, structure and progress achieved. Patient engagement camps and patient-focused workshops conducted since early 2021 have involved more than 150 patients, family caregivers and healthcare providers. A patient registry was established by screening 1500 patients eligible for advanced therapies with 157 identified to benefit from advanced treatments for SCD. Out of which 22 patients received ExBT, and human leucocyte antigen typing was conducted on 127 individuals to establish a registry of family members with potential to be HSCT donors. Target product profiles were devised for minimum and optimum criteria of GT products to guide drug discovery and development efforts, and qualitative research was conducted to investigate factors anticipated to influence successful adoption of GTs for SCD in Africa. The programme’s multifaceted components have been enabled by institutional networks and collaborations established at national, regional and global levels. The programme presented opportunities to deliver cost-effective advanced treatment and curative options for SCD in Tanzania and lessons learnt may be applicable to inform similar efforts in other African regions where SCD is highly endemic.
- 27 January 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (1) , e017878
Open AccessStrengthening advanced therapy for sickle cell disease in Africa: experience from sickle cell disease centre in Dar es Salaam, Tanzania
Despite progress in healthcare services for individuals living with sickle cell disease (SCD) in Africa, substantial gaps remain in advanced treatments for SCD. To help address this burden, Tanzania has established one of the largest single-centre SCD programmes in the world and developed an advanced therapy programme for SCD focused on patient engagement and advocacy, clinical activities involving exchange blood transfusion (ExBT) and haematopoietic stem cell transplant (HSCT), gene therapy (GT) preparedness, and enabling partnerships. This report describes the programme’s genesis, structure and progress achieved. Patient engagement camps and patient-focused workshops conducted since early 2021 have involved more than 150 patients, family caregivers and healthcare providers. A patient registry was established by screening 1500 patients eligible for advanced therapies with 157 identified to benefit from advanced treatments for SCD. Out of which 22 patients received ExBT, and human leucocyte antigen typing was conducted on 127 individuals to establish a registry of family members with potential to be HSCT donors. Target product profiles were devised for minimum and optimum criteria of GT products to guide drug discovery and development efforts, and qualitative research was conducted to investigate factors anticipated to influence successful adoption of GTs for SCD in Africa. The programme’s multifaceted components have been enabled by institutional networks and collaborations established at national, regional and global levels. The programme presented opportunities to deliver cost-effective advanced treatment and curative options for SCD in Tanzania and lessons learnt may be applicable to inform similar efforts in other African regions where SCD is highly endemic.
- Open Access
- 1 March 2024
- Published by Taylor & Francis in Pediatric Health, Medicine and Therapeutics
- Vol. ume 15, 121-128
Dental Caries in Children with Sickle Cell Disease and Its Association with the Use of Hydroxyurea and Penicillin Prophylaxis in Dar Es Salaam
Purpose: This comparative study sets out to report dental caries status among individuals with Sickle Cell Disease (HbSS) against those with sickle cell trait (HbSA) and those without the disease (HbAA) as controls. The study further assessed the impact of penicillin chemoprophylaxis and hydroxyurea use on dental caries among Sickle Cell Disease participants. Methods: This was a comparative cross-sectional study in which 93 children aged 30 to 60 months were recruited. There were 60 participating children who had SCD (HbSS), 17 with SCD trait (HbAS) and 16 were without SCD or SC trait (HbAA). A questionnaire was used to record sociodemographic details including mean age in months and sex and on haemoglobin genotype for all the participants. Specifically, for the participants with HbSS, information on their whether they are taking hydroxyurea (HU), and penicillin chemoprophylaxis was recorded. To assess the prevalence of dental caries, clinical examination of all primary maxillary and mandibular teeth to determine the presence or absence of dental caries lesions was also recorded. Results: A total of 1197 teeth from 93 children were examined, whereby, 45 (2.4%) of them had dental caries. The participating children with HbAA genotype (6.6%, N=21) had more dental caries than their HbSS counterparts (2.0%, N=24), while none of the participants with HbAS exhibited dental caries. Among the participants with HbSS, males and those who use HU were 3.79 and 3.07 times more likely to have dental caries than their counterparts, female and non-users of HU, respectively. Conclusion: Dental caries was observed to be low among participants with HbSS when compared to those with HbAA. More research utilizing more robust methodologies is recommended.
- 1 March 2024
- Published by Taylor & Francis in Pediatric Health, Medicine and Therapeutics
- Vol. ume 15, 121-128
Open AccessDental Caries in Children with Sickle Cell Disease and Its Association with the Use of Hydroxyurea and Penicillin Prophylaxis in Dar Es Salaam
Purpose: This comparative study sets out to report dental caries status among individuals with Sickle Cell Disease (HbSS) against those with sickle cell trait (HbSA) and those without the disease (HbAA) as controls. The study further assessed the impact of penicillin chemoprophylaxis and hydroxyurea use on dental caries among Sickle Cell Disease participants. Methods: This was a comparative cross-sectional study in which 93 children aged 30 to 60 months were recruited. There were 60 participating children who had SCD (HbSS), 17 with SCD trait (HbAS) and 16 were without SCD or SC trait (HbAA). A questionnaire was used to record sociodemographic details including mean age in months and sex and on haemoglobin genotype for all the participants. Specifically, for the participants with HbSS, information on their whether they are taking hydroxyurea (HU), and penicillin chemoprophylaxis was recorded. To assess the prevalence of dental caries, clinical examination of all primary maxillary and mandibular teeth to determine the presence or absence of dental caries lesions was also recorded. Results: A total of 1197 teeth from 93 children were examined, whereby, 45 (2.4%) of them had dental caries. The participating children with HbAA genotype (6.6%, N=21) had more dental caries than their HbSS counterparts (2.0%, N=24), while none of the participants with HbAS exhibited dental caries. Among the participants with HbSS, males and those who use HU were 3.79 and 3.07 times more likely to have dental caries than their counterparts, female and non-users of HU, respectively. Conclusion: Dental caries was observed to be low among participants with HbSS when compared to those with HbAA. More research utilizing more robust methodologies is recommended.
- Open Access
- 30 December 2022
- Published by African Journals Online (AJOL) in Tanzania Journal of Science
- Vol. 48 (4) , 832-842
Oral Impacts on Daily Performances among People Living with Human Immunodeficiency Virus on HAART Era Attending Care and Treatment Clinics in Dar es Salaam, Tanzania
Oral disease/conditions are reported to have negative effects on the quality of life of People Living with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (PLWHIV/AIDS). This study aimed to assess the prevalence and causes of oral impacts on daily performances (OIDP) and its associated factors among PLWHIV/AIDS. A cross-sectional study was conducted among 218 PLWHIV/AIDS attending two HIV Care and Treatment Centres (CTCs) in Dar es Salaam. The study utilized a structured interview schedule containing questions on socio-demography and a single item of global oral health measure on the perception of current oral health status (OHS). A Swahili version of an OIDP inventory was used to assess the impacts of oral conditions on participants’ daily performances. Frequency distribution, chi-square, and logistic regression analyses were conducted (p < 0.05). Participants’ age ranged from 20 to 70 years, mean of 41.15 SD 10.7. About 70% (n = 154) of the participants perceived their oral health status (OHS) as good. The prevalence of OIDP (³ 1) was 26.1% (n = 57). The most affected performances reported were eating and chewing food followed by maintaining the usual emotional state without being irritable. Toothache was the main cause of impacts on all daily performances except ‘speaking and pronouncing clearly’ which was caused by oral ulcer. Age (p = 0.025) and perceived oral health status (p = 0.000) were significantly associated with OIDP. More studies on biological and behavioural factors are recommended to support inclusion of oral health in CTCs. Keywords: Care and Treatment Centres; HAART; HIV; Oral health; Quality of life
- 30 December 2022
- Published by African Journals Online (AJOL) in Tanzania Journal of Science
- Vol. 48 (4) , 832-842
Open AccessOral Impacts on Daily Performances among People Living with Human Immunodeficiency Virus on HAART Era Attending Care and Treatment Clinics in Dar es Salaam, Tanzania
Oral disease/conditions are reported to have negative effects on the quality of life of People Living with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (PLWHIV/AIDS). This study aimed to assess the prevalence and causes of oral impacts on daily performances (OIDP) and its associated factors among PLWHIV/AIDS. A cross-sectional study was conducted among 218 PLWHIV/AIDS attending two HIV Care and Treatment Centres (CTCs) in Dar es Salaam. The study utilized a structured interview schedule containing questions on socio-demography and a single item of global oral health measure on the perception of current oral health status (OHS). A Swahili version of an OIDP inventory was used to assess the impacts of oral conditions on participants’ daily performances. Frequency distribution, chi-square, and logistic regression analyses were conducted (p < 0.05). Participants’ age ranged from 20 to 70 years, mean of 41.15 SD 10.7. About 70% (n = 154) of the participants perceived their oral health status (OHS) as good. The prevalence of OIDP (³ 1) was 26.1% (n = 57). The most affected performances reported were eating and chewing food followed by maintaining the usual emotional state without being irritable. Toothache was the main cause of impacts on all daily performances except ‘speaking and pronouncing clearly’ which was caused by oral ulcer. Age (p = 0.025) and perceived oral health status (p = 0.000) were significantly associated with OIDP. More studies on biological and behavioural factors are recommended to support inclusion of oral health in CTCs. Keywords: Care and Treatment Centres; HAART; HIV; Oral health; Quality of life
- Open Access
- 7 November 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (11) , 2223
Barriers and Facilitators of Availability of Hydroxyurea for Sickle Cell Disease in Tanzania; A Qualitative Study of Pharmaceutical Manufacturers, Importers, and Regulators
Despite three decades of proven safety and effectiveness of hydroxyurea in modifying sickle cell disease (SCD), its accessibility is limited in Sub-Saharan Africa, which shares 75% of the world’s SCD burden. Therefore, it is time to explore the barriers and facilitators for manufacturing and importation of hydroxyurea for SCD in Tanzania. This was qualitative research that employed a case study approach. Purposive sampling followed by an in-depth interview (IDI) using a semi-structured questionnaire aspired by data saturation enabled us to gather data from 10 participants. The study participants were people with more than three years of experience in pharmaceuticals importation, manufacturing, and regulation. The audio-recorded data were verbatim transcribed and analyzed using thematic analysis. Two themes were generated. The first comprised barriers for importation and manufacturing of hydroxyurea with sub-themes such as inadequate awareness of SCD and hydroxyurea, limited market, and investment viability. The second comprised opportunities for importation and manufacturing of hydroxyurea with sub-themes such as awareness of activities performed by medicines regulatory authority and basic knowledge on SCD and hydroxyurea. Inadequate understanding of SCD, hydroxyurea, and orphan drug regulation are major issues that aggravate the concern for limited market and investment viability. Existing opportunities are a starting point towards increasing the availability of hydroxyurea.
- 7 November 2022
- Published by MDPI AG in Healthcare
- Vol. 10 (11) , 2223
Open AccessBarriers and Facilitators of Availability of Hydroxyurea for Sickle Cell Disease in Tanzania; A Qualitative Study of Pharmaceutical Manufacturers, Importers, and Regulators
Despite three decades of proven safety and effectiveness of hydroxyurea in modifying sickle cell disease (SCD), its accessibility is limited in Sub-Saharan Africa, which shares 75% of the world’s SCD burden. Therefore, it is time to explore the barriers and facilitators for manufacturing and importation of hydroxyurea for SCD in Tanzania. This was qualitative research that employed a case study approach. Purposive sampling followed by an in-depth interview (IDI) using a semi-structured questionnaire aspired by data saturation enabled us to gather data from 10 participants. The study participants were people with more than three years of experience in pharmaceuticals importation, manufacturing, and regulation. The audio-recorded data were verbatim transcribed and analyzed using thematic analysis. Two themes were generated. The first comprised barriers for importation and manufacturing of hydroxyurea with sub-themes such as inadequate awareness of SCD and hydroxyurea, limited market, and investment viability. The second comprised opportunities for importation and manufacturing of hydroxyurea with sub-themes such as awareness of activities performed by medicines regulatory authority and basic knowledge on SCD and hydroxyurea. Inadequate understanding of SCD, hydroxyurea, and orphan drug regulation are major issues that aggravate the concern for limited market and investment viability. Existing opportunities are a starting point towards increasing the availability of hydroxyurea.
- Open Access
- 4 June 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (11) , 6871
The Effects of Sickle Cell Disease on the Quality of Life: A Focus on the Untold Experiences of Parents in Tanzania
Tanzania is among the top five countries with a high burden of sickle cell disease (SCD) in the world. Even though the effects of SCD on quality of life have been documented in other countries including Nigeria and the United States of America, few are known from Tanzania. Therefore, this study focused on evaluating the effects of SCD on the quality of life among children living with SCD and their parents. The study employed a qualitative approach to interview purposively selected parents of children who have lived with SCD and have used hydroxyurea (HU) for more than 3 years. The in-depth interviews were conducted with 11 parents of children with SCD at the Muhimbili University of Health and Allied Sciences (MUHAS) in Dar-es-salaam, Tanzania. A semi-structured interview guide was used. Interviews were audio-recorded, transcribed, and thematically analyzed. Three themes were generated including psycho-social effects: family conflicts and divorce, limited access to education, stress and fear; financial effects: Employment limitation, reduced efficiency and productivity, loss of job and lack of self-keeping expenses; and physical effects: physical disability and dependence, and burden of the frequent crisis. Children living with SCD and their parents suffer psycho-social, financial, and physical impacts of the disease. Appropriate interventions should be introduced to minimize the observed effects as ways of improving the quality of life of the individuals living with SCD and their caregivers.
- 4 June 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (11) , 6871
Open AccessThe Effects of Sickle Cell Disease on the Quality of Life: A Focus on the Untold Experiences of Parents in Tanzania
Tanzania is among the top five countries with a high burden of sickle cell disease (SCD) in the world. Even though the effects of SCD on quality of life have been documented in other countries including Nigeria and the United States of America, few are known from Tanzania. Therefore, this study focused on evaluating the effects of SCD on the quality of life among children living with SCD and their parents. The study employed a qualitative approach to interview purposively selected parents of children who have lived with SCD and have used hydroxyurea (HU) for more than 3 years. The in-depth interviews were conducted with 11 parents of children with SCD at the Muhimbili University of Health and Allied Sciences (MUHAS) in Dar-es-salaam, Tanzania. A semi-structured interview guide was used. Interviews were audio-recorded, transcribed, and thematically analyzed. Three themes were generated including psycho-social effects: family conflicts and divorce, limited access to education, stress and fear; financial effects: Employment limitation, reduced efficiency and productivity, loss of job and lack of self-keeping expenses; and physical effects: physical disability and dependence, and burden of the frequent crisis. Children living with SCD and their parents suffer psycho-social, financial, and physical impacts of the disease. Appropriate interventions should be introduced to minimize the observed effects as ways of improving the quality of life of the individuals living with SCD and their caregivers.
- Open Access
Barriers and Facilitators of Use of Hydroxyurea among Children with Sickle Cell Disease: Experiences of Stakeholders in Tanzania
Factors contributing to low use of HU among SCD patients exist in high-income countries. The latter leaves a drift of literature on factors for low utilization of HU in developing countries. This study aimed to explore the factors influencing the use of HU in the management of SCD in Tanzania. A qualitative study was employed to interview purposively selected participants for this study. The in-depth interviews were conducted with 11 parents of children with SCD, four medical doctors working at sickle cell clinics, and two representatives of the national health insurance fund (NHIF). Interviews were audio-recorded, transcribed, and thematically analysed. Barriers identified were misconception of parents on SCD, financial constraints, regulatory restrictions, worries and fears of medical doctors on the acceptability of HU, shortages of laboratory equipment and consumables, and limited availability of HU. Adequate knowledge of the parents and medical doctors on SCD and HU and opportunities for HU accessibility were the facilitators identified. The utilization of HU by the individual with SCD is affected by several factors, from individual to policy level. Nevertheless, parents of children with SCD and medical doctors working in sickle cell clinics demonstrated good knowledge of the diseases and HU.
Open AccessBarriers and Facilitators of Use of Hydroxyurea among Children with Sickle Cell Disease: Experiences of Stakeholders in Tanzania
Factors contributing to low use of HU among SCD patients exist in high-income countries. The latter leaves a drift of literature on factors for low utilization of HU in developing countries. This study aimed to explore the factors influencing the use of HU in the management of SCD in Tanzania. A qualitative study was employed to interview purposively selected participants for this study. The in-depth interviews were conducted with 11 parents of children with SCD, four medical doctors working at sickle cell clinics, and two representatives of the national health insurance fund (NHIF). Interviews were audio-recorded, transcribed, and thematically analysed. Barriers identified were misconception of parents on SCD, financial constraints, regulatory restrictions, worries and fears of medical doctors on the acceptability of HU, shortages of laboratory equipment and consumables, and limited availability of HU. Adequate knowledge of the parents and medical doctors on SCD and HU and opportunities for HU accessibility were the facilitators identified. The utilization of HU by the individual with SCD is affected by several factors, from individual to policy level. Nevertheless, parents of children with SCD and medical doctors working in sickle cell clinics demonstrated good knowledge of the diseases and HU.